Physician profile
Michael J Geiger
NPI 1235211491
$1,237.80
in general payments reported to CMS, 2019-2025
14 companies · $27.78 in 2025
The $27.78 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $70.52 · 2021: $162 · 2022: $41.38 · 2023: $135 · 2024: $219 · 2025: $27.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.43 | 2019-2024 | Tezspire |
| Novo Nordisk INC | $130.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $122.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.71 | 2019-2021 | |
| Cranial Technologies, INC | $82.58 | 2019-2024 | Doc Band |
| Janssen Pharmaceuticals, INC | $72.16 | 2019-2022 | |
| Glaxosmithkline, LLC. | $68.79 | 2019-2024 | Shingrix, Arexvy |
| Pfizer INC. | $65.50 | 2019-2023 | |
| Amgen INC. | $53.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.81 | 2019-2021 | |
| Abbott Laboratories | $19.24 | 2021 | |
| Allergan, INC. | $16.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.